

Tuberculosis profile: Slovenia

Population 2020: 2.1 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	86 (74-100)	4.1 (3.5-4.8)
HIV-positive TB incidence	0 (0-2)	0 (0-0.1)
HIV-negative TB mortality	14 (14-15)	0.69 (0.68-0.7)
HIV-positive TB mortality	0 (0-0)	0 (0-0.02)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2020	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	17% (14-19)

TB case notifications, 2020

Total new and relapse	75
- % tested with rapid diagnostics at time of diagnosis	83%
- % with known HIV status	77%
- % pulmonary	85%
- % bacteriologically confirmed ^	97%
- % children aged 0-14 years	0%
- % women (aged ≥15 years)	40%
- % men (aged ≥15 years)	60%
Total cases notified	77


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care**, 2020


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	1
Patients started on treatment - MDR/RR-TB ^^^	1
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	1

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	70%	98
Previously treated cases, excluding relapse, registered in 2019	67%	3
HIV-positive TB cases registered in 2019	100%	1
MDR/RR-TB cases started on second-line treatment in 2018		
XDR-TB cases started on second-line treatment in 2018		


Incidence, Notified cases by age group and sex, 2020

(Number)



Cases attributable to five risk factors, 2020

(Number)



TB preventive treatment, 2020

% of HIV-positive people (newly enrolled in care) on preventive treatment

% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100% (100-100)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed

Generated 2021-12-01 by [the World Health Organization](#)

Version 2.1, Source code on [Github](#). Data are also available on the TB Report app for [iOS](#) and [Android](#) and as [CSV files](#).